4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      MST2 silencing induces apoptosis and inhibits tumor growth for estrogen receptor alpha-positive MCF-7 breast cancer.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Mammalian sterile 20-like kinase 1/2 (MST1/2) plays an important role in cell growth and apoptosis and functions as a tumor suppressor. Previously, we showed that MST2 overexpression activates Estrogen receptor alpha (ERα) in human breast cancer MCF-7 cells in the absence of a ligand. Here, we examined the role of MST2 in the growth of ER-positive MCF-7 cells. Cell cycle, apoptosis, and mammosphere formation assay method were implemented to detect the biological effects of MST2 ablation on the growth of MCF-7 cells in vitro. The effect of MST2-siRNA on MCF-7 cells tumor growth in vivo was studied in tumor-bearing mouse model. Kaplan-Meier plotter analysis was used to determine the effect of MST2 on overall survival in breast cancer patients. MST2 overexpression increased cell viability marginally. The ablation of MST2 using siRNA dramatically suppressed the viability of the MCF-7 cells, but not ER-negative MDA-MB-231 breast cancer cells. Furthermore, MST2 knockdown increased caspase-dependent apoptosis and led to decreased mammosphere formation. Treatment of MCF-7 tumor-bearing mice with MST2 siRNA significantly inhibited tumor growth. The tumor weight was reduced further when tamoxifen was added. Patients with ER-positive breast cancer with low MST2 expression had better overall survival than did those with high MST2 expression in Kaplan-Meier survival analyses using public datasets. Our results provide new insight into the role of MST2, a key component of the Hippo signaling pathway, in mediating breast cancer progression.

          Related collections

          Author and article information

          Journal
          Toxicol Appl Pharmacol
          Toxicology and applied pharmacology
          Elsevier BV
          1096-0333
          0041-008X
          December 01 2020
          : 408
          Affiliations
          [1 ] Department of Integrative Bioscience and Biotechnology, College of Life Science, Sejong University, Kwangjin-gu, Seoul 05006, South Korea.
          [2 ] Department of Immunology, School of Medicine, Konkuk University, Chungju 380-701, South Korea.
          [3 ] Department of Biochemistry, College of Medicine, Chungbuk National University, Cheongju, Chungbuk 28644, South Korea.
          [4 ] Department of Immunology, School of Medicine, Konkuk University, Chungju 380-701, South Korea. Electronic address: hanhd@kku.ac.kr.
          [5 ] Department of Integrative Bioscience and Biotechnology, College of Life Science, Sejong University, Kwangjin-gu, Seoul 05006, South Korea. Electronic address: yjlee@sejong.ac.kr.
          Article
          S0041-008X(20)30383-5
          10.1016/j.taap.2020.115257
          33007383
          a7e9049e-156d-492c-bb46-36676074ebc8
          Copyright © 2020 Elsevier Inc. All rights reserved.
          History

          ERα-positive breast cancer,Gene silencing,MST2,Nanoparticle,siRNA

          Comments

          Comment on this article